Ensysce Biosciences, Inc. (ENSC) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: August 5, 2026
Company: Ensysce Biosciences, Inc.
Event: Completion of a business combination (Merger) with Cy Biopharma, Inc. ("Cy") and a concurrent private placement financing (PIPE).
On August 5, 2026, Ensysce acquired Cy through a two-step merger structure. Cy became a wholly-owned subsidiary of Ensysce. The transaction was structured to qualify as a tax-free reorganization for U.S. federal income tax purposes.
Key Financial Metrics and Transaction Terms
Financing (PIPE):
- Total Aggregate Purchase Price: Approximately $43 million.
- Instrument: 120,260 shares of Series C Preferred Stock (convertible 1:1,000 into Common Stock).
- Tranche 1 (Initial Closing): 66,811 shares at $321.79 per share (approx. $0.32179 as-converted). Expected closing: August 7, 2026.
- Tranche 2 (Milestone Closing): 53,449 shares at $402.24 per share (approx. $0.40224 as-converted), contingent on achieving a clinical trial milestone.
Merger Consideration:
- Equity Issued to Cy Shareholders: 282,122 shares of Series C Preferred Stock.
- Conversion: Each Series C share converts to 1,000 shares of Common Stock upon stockholder approval.
Advisory Fees:
- Tungsten Partners LLC: $100,000 cash, 100,000 restricted stock units (RSUs), and a $15,000 monthly advisory fee (paid since March 2026).
- H.C. Wainwright & Co., LLC: $250,000 transaction fee and $400,000 fairness opinion fee.
Debt and Liquidity: The filing does not provide specific pre-transaction debt balances or cash on hand. Liquidity is expected to be bolstered by the $43 million PIPE financing.
Material Changes and Corporate Actions
Acquisition: Cy Biopharma, Inc. is now a wholly-owned subsidiary of Ensysce Biosciences, Inc.
Capital Structure Changes:
- Series B Preferred Stock: Eliminated via an Omnibus Amendment and Termination Agreement (OATA) with 3i, LP. All outstanding Series B shares converted to 3,229,276 shares of Common Stock (910,905 issued to 3i; 2,318,371 held in abeyance).
- Series C Preferred Stock: New class created for Cy shareholders and PIPE investors. Non-voting unless specific adverse actions are proposed. Convertible to Common Stock.
- Warrants: Warrants held by 3i converted into 7,182.517 shares of Series C Preferred Stock.
Management Changes:
- Lynn Kirkpatrick: Resigned as President effective August 5, 2026. Remains CEO until stockholder approval of the Merger proposals.
- James Morrison: Appointed President and Director effective August 5, 2026. To become CEO upon stockholder approval of the Merger proposals.
Guidance, Outlook, and Risks
Stockholder Approval Required: The Company must hold a stockholders' meeting to approve: (i) the conversion of Series C Preferred Stock into Common Stock, and (ii) a potential Charter Amendment to authorize sufficient shares or effectuate a reverse stock split to maintain Nasdaq listing standards.
Lock-Up Agreements: Certain Cy stockholders and Company directors/officers are subject to a 180-day lock-up on the sale or transfer of shares held at Closing.
Registration Rights: The Company must file resale registration statements for PIPE securities and Series C securities within 90 days of the Financing Closing Date and Merger Closing, respectively.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains projections regarding clinical milestones, cash runway, and the combined company's pipeline, which are subject to significant uncertainty.
- Beneficial Ownership Limitation: 3i is subject to a 4.99% beneficial ownership limitation (expandable to 9.99% with notice), with excess shares held in abeyance.
- Financial Statements: Pro forma financial information and financial statements of the acquired business are not included in this filing and are expected to be filed within 71 days.
Key Facts for Investor Verification
- Financing Milestone: Verify the specific clinical trial milestone required to trigger the second tranche of the $43 million PIPE financing.
- Stockholder Vote: Confirm the date of the stockholders' meeting and the outcome of the vote on the Conversion Proposal and Charter Amendment.
- Pro Forma Capitalization: Review the upcoming pro forma financial information to understand the post-transaction ownership structure and dilution.
- Series C Terms: Review the Certificate of Designation (Exhibit 3.2) for specific redemption rights and conversion limitations.
- 3i Abeyance Account: Monitor the status of the 2.3 million shares of Common Stock held in abeyance for 3i and the conditions for their release.